Cargando…

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

BACKGROUND: Although hydromethylthionine is a potent tau aggregation inhibitor, no difference was found in either of two Phase III trials in mild to moderate Alzheimer’s disease (AD) comparing doses in the range 150–250 mg/day with 8 mg/day intended as a control. OBJECTIVE: To determine how drug exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schelter, Bjoern O., Shiells, Helen, Baddeley, Thomas C., Rubino, Christopher M., Ganesan, Harish, Hammel, Jeffrey, Vuksanovic, Vesna, Staff, Roger T., Murray, Alison D., Bracoud, Luc, Riedel, Gernot, Gauthier, Serge, Jia, Jianping, Bentham, Peter, Kook, Karin, Storey, John M.D., Harrington, Charles R., Wischik, Claude M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918900/ https://www.ncbi.nlm.nih.gov/pubmed/31658058 http://dx.doi.org/10.3233/JAD-190772

Ejemplares similares

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
por: Shiells, Helen, et al.
Publicado: (2020)

Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier
por: Bentham, Peter, et al.
Publicado: (2021)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
por: Kondak, Constantin, et al.
Publicado: (2023)

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
por: Wischik, Claude M., et al.
Publicado: (2022)

Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
por: Arastoo, Mohammad, et al.
Publicado: (2023)

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
por: Wilcock, Gordon K., et al.
Publicado: (2017)

Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks
por: Schwab, Karima, et al.
Publicado: (2021)

Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia
por: Vuksanović, Vesna, et al.
Publicado: (2021)

Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
por: Wischik, Claude M., et al.
Publicado: (2018)

HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
por: Santos, Renato X., et al.
Publicado: (2022)

Vascular risk factors affect different brain regions in people with Alzheimer’s disease
por: Tripathi, S., et al.
Publicado: (2022)

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
por: Schwab, Karima, et al.
Publicado: (2018)

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia
por: Lemke, Nora, et al.
Publicado: (2021)

Detection of time-, frequency- and direction-resolved communication within brain networks
por: Crouch, Barry, et al.
Publicado: (2018)

Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer’s disease and frontotemporal lobar degeneration
por: Cranston, Anna L, et al.
Publicado: (2020)

Brain morphometric similarity and flexibility
por: Vuksanović, Vesna
Publicado: (2022)

Inferring the underlying multivariate structure from bivariate networks with highly correlated nodes
por: Loske, Philipp, et al.
Publicado: (2022)

Dynamics of large-scale neuronal networks of the human cortex functional connectivity
por: Vuksanović, Vesna, et al.
Publicado: (2012)

Modeling brain functional connectivity at rest
por: Vuksanović, Vesna, et al.
Publicado: (2013)

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
por: Melis, Valeria, et al.
Publicado: (2015)

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 2016, 6, 19
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Apolipoprotein ε4 modifies obesity-related atrophy in the hippocampal formation of cognitively healthy adults
por: Coad, Bethany M., et al.
Publicado: (2022)

Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model
por: Riedel, Gernot, et al.
Publicado: (2020)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
por: Al-Hilaly, Youssra K., et al.
Publicado: (2022)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease
por: Harrington, Charles R., et al.
Publicado: (2015)

Atrophy patterns in isolated subscapularis lesions
por: Seppel, Gernot, et al.
Publicado: (2021)

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

A Metabotropic Glutamate Receptor Regulates Transmitter Release from Cone Presynaptic Terminals in Carp Retinal Slices
por: Hirasawa, Hajime, et al.
Publicado: (2002)

Attitudes towards transactional data donation and linkage in a longitudinal population study: evidence from the Avon Longitudinal Study of Parents and Children
por: Skatova, Anya, et al.
Publicado: (2021)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
por: Arastoo, Mohammad, et al.
Publicado: (2020)

Tau (297‐391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer’s disease brain
por: Al‐Hilaly, Youssra K., et al.
Publicado: (2019)

Granger causal time-dependent source connectivity in the somatosensory network
por: Gao, Lin, et al.
Publicado: (2015)

The increase in health care costs associated with muscle weakness in older people without long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe (SHARE)
por: Steffl, Michal, et al.
Publicado: (2017)

Design, data management, and population baseline characteristics of the PERFORM magnetic resonance imaging project
por: Maeder, P., et al.
Publicado: (2010)

Transcriptional activation of muscle atrophy promotes cardiac muscle remodeling during mammalian hibernation
por: Zhang, Yichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_itk267bapnsuvg9ca5rgd12ktm